Abstracts tagged "Gene Expression"

Abstract Number: 1908 • 2015 ACR/ARHP Annual Meeting
Macitentan Responsiveness Supports the Validity of a Murine Model of Pulmonary Hypertension in Scleroderma Associated with Altered Tgfbeta/BMPR2 Signalling
Emma C. Derrett-Smith¹, Vincent Sobanski², Adrian Gilbane², Sarah Trinder³, Yasmina Bauer⁴, Berengère Renault⁴, Marc Iglarz⁴, David Abraham⁵, Alan M. Holmes⁶ and Christopher P. Denton⁷, ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Division of Medicine, London, United Kingdom, ²UCL Division of Medicine, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Disease, UCL Division of Medicine, London, United Kingdom, ⁴Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, ⁵Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁶Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ⁷Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Pulmonary arterial hypertension (PAH) is an important complication of systemic sclerosis (SSc) that occurs in around 10% of cases. We have previously shown that…
Abstract Number: 2827 • 2015 ACR/ARHP Annual Meeting
Analysis of HLA-B27 Transgenic Rats Reveals Specific Gut Transcriptome and Microbiome Signatures Associated with Inflammation
Tejpal Gill¹, Mark Asquith², Stephen Brooks¹, James T. Rosenbaum³ and Robert A. Colbert⁴, ¹NIAMS/NIH, Bethesda, MD, ²OHSU, Portland, OR, ³Devers Eye Institute, Legacy Hospital system, Portland, OR, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: HLA-B27 and human beta 2-microglobulin expression in rats (transgenic; TG) induces a spontaneous inflammatory disease resembling human spondyloarthritis (SpA) with associated gastrointestinal inflammation. While…
Abstract Number: 102 • 2015 ACR/ARHP Annual Meeting
Xanthine Oxidase Gene Variants and Their Association with Blood Pressure and Incident Hypertension: A Population Based Study
Lieke E.J.M. Scheepers¹, Jan A. Staessen^2,3, Lutgarde Thijs², Erika Salvi⁴, Annelies Boonen⁵ and Ilja C.W. Arts⁶, ¹Department of Internal Medicine, Division of Rheumatology, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, Netherlands, ²Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology KU Leuven, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium, ³R & D Group VitaK, Maastricht University, Maastricht, Netherlands, ⁴Department of Health Sciences, University of Milan, Milan, Italy, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁶Department of Epidemiology, CAPHRI School for Public Health and Primary Care, CARIM School for Cardiovascular Diseases, and MaCSBio Maastricht Centre for Systems Biology, Maastricht University, Maastricht, Netherlands
Background/Purpose: Uric acid (UA) has been associated with blood pressure (BP) and hypertension. During the final stage of purine metabolism, xanthine oxidoreductase (XOR) breaks down…
Abstract Number: 1915 • 2015 ACR/ARHP Annual Meeting
Pathogenetic Overlap Between Localised and Systemic Scleroderma: A Study of Nodular and Keloidal Morphea Occurring in Systemic Sclerosis
Emma C. Derrett-Smith¹, Nataliya Gak², Svetlana I. Nihtyanova³, Voon H. Ong³, Victoria Swale², Cate Orteu² and Christopher P. Denton⁴, ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Division of Medicine, London, United Kingdom, ²Royal Free London NHS Foundation Trust, London, United Kingdom, ³Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁴Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Localised scleroderma can occur in overlap with systemic sclerosis (SSc); nodular and keloidal morphea are rare subtypes but can be disfiguring and challenging to…
Abstract Number: 3000 • 2015 ACR/ARHP Annual Meeting
Intrinsic Gene Expression Subset Predicts Improvement in Systemic Sclerosis Patients during Dasatinib (SprycelTM) Therapy
Viktor Martyanov¹, Jonathan Goldin², Kim Hyun³, Oumar Sy⁴, Wendy Hayes⁴, Shuyan Du⁴, Michael Whitfield¹ and John Varga⁵, ¹Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, ²David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ³Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL
Background/Purpose: Intrinsic gene expression subsets are molecular pathway-driven subtypes of systemic sclerosis (SSc) that have been reproduced across multiple cohorts of SSc patients. The goal…
Abstract Number: 2978 • 2014 ACR/ARHP Annual Meeting
Characterization of the Sjögren’s Syndrome Intergenic Non-Coding RNA 1 (SSINCR1)
John A. Ice¹, He Li^2,3, Indra Adrianto², Mikhail G. Dozmorov⁴, Astrid Rasmussen⁵, Graham B. Wiley¹, Jennifer A. Kelly¹, Kimberly S. Hefner⁶, Donald U. Stone⁷, Raj Gopalakrishnan⁸, David M. Lewis⁹, Stephen Young⁹, Michael D. Rohrer⁸, Juan-Manuel Anaya¹⁰, Swamy Venuturupalli¹¹, Barbara M. Segal¹², Nelson L. Rhodus¹³, Lida Radfar¹⁴, Michael H. Weisman¹⁵, Judith A. James^16,17, Courtney G. Montgomery¹⁸, R. Hal Scofield^19,20,21, Patrick M. Gaffney¹, Linda F. Thompson²², A. Darise Farris²³, Susan Kovats¹, Jonathan D. Wren¹, Kathy L. Sivils²⁴ and Christopher J. Lessard²⁵, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁷Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁹College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ¹¹Cedars-Sinai Medical Center, West Hollywood, CA, ¹²Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹³University of Minnesota, Minneapolis, MN, ¹⁴College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁵Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁶Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁷Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ²⁰College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²²Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²³Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, ²⁴Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁵825 N.E. 13th St., Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose Sjögren’s syndrome (SS) is a common autoimmune disorder characterized by immune-mediated exocrine gland destruction and systemic inflammatory responses that contribute to clinical heterogeneity. Widespread…
Abstract Number: 1723 • 2014 ACR/ARHP Annual Meeting
Identification of the Microbiome As a Potential Trigger of Systemic Sclerosis By Metagenomic RNA-Sequencing of Skin Biopsies
Michael Johnson¹, Zhenghui Li¹, Michelle Dimon², Tammara A. Wood¹, Robert Lafyatis³, Sarah Arron² and Michael Whitfield⁴, ¹Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Dermatology, University of California, San Francisco, San Francisco, CA, ³Arthritis Center, Boston University, Boston, MA, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic sclerosis (SSc) is a rare and poorly understood systemic autoimmune disease that results in skin fibrosis and severe internal organ involvement. There…
Abstract Number: 2878 • 2014 ACR/ARHP Annual Meeting
G Protein Signaling Modulator 3 (GPSM3) Deficiency Is Protective in Inflammatory Arthritis Models and Altered GPSM3 Gene Products Correlate with Single Nucleotide Polymorphisms in Humans
Teresa K. Tarrant¹, D. Stephen Serafin², Elizabeth Sugg², Roman Timoshchenko², Matthew J. Billard², David P. Siderovski³ and Kristy Richards⁴, ¹Medicine/Rheumatology, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Physiology and Pharmacology, West Virginia University School of Medicine, Morgantown, WV, ⁴Medicine, Dept. of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose GPSM3, a newly described regulator of heterotrimeric G protein signaling, is selectively expressed in hematopoietic cells with high expression in monocytes. We have shown…
Abstract Number: 1619 • 2014 ACR/ARHP Annual Meeting
Interferon Dysregulation in an Academic SLE Cohort Is Associated with Distinct Signaling Differences in Blood Neutrophils Versus PBMCs
David Drubin¹, Xiang Guo², Linglin Yang³, Rong Zeng³, Yuling Wu³, Mustimbo EliPollard Roberts³, Reynald Lescarbeau¹, Aaron Van Hooser¹, Michael Macoritto¹, Michelle Petri⁴ and Wendy White⁵, ¹Selventa, Cambridge, MA, ²Translational Sciences, MedImmune LLC, Gaithersburg, MD, ³MedImmune LLC, Gaithersburg, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Translational Sciences, MedImmune, Gaithersburg, MD
Background/Purpose Interferons (IFNs) have long been implicated in the pathogenesis of systemic lupus erythematosus (SLE). However, the specific consequences of the IFN activity have not…
Abstract Number: 2798 • 2014 ACR/ARHP Annual Meeting
C5orf30 a Novel Regulator of Inflammation and Tissue Damage in Rheumatoid Arthritis
Munitta Muthana¹, Sarah Hawtree¹, Holly Davies², Hannah Roberts¹, Sachin Khetan¹, Mohammed Akil³, Fiona Wright¹, Barbara Ciani⁴, Ursula Fearon⁵, DJ Veale⁶ and Anthony G. Wilson⁷, ¹Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ²University of Sheffield, Sheffield, United Kingdom, ³Rheumatology Department, Sheffield South Yorkshire, United Kingdom, ⁴Chemistry, University of Sheffield, Sheffield, United Kingdom, ⁵Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ⁶Consultant Rheumatologist, St. Vincent’s University Hospital, Dublin, Ireland, ⁷Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose A recent genome wide association study identified the variant rs26232 in the first intron of the uncharacterized gene, C5orf30, as a rheumatoid arthritis (RA)…
Abstract Number: 1617 • 2014 ACR/ARHP Annual Meeting
Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes
Zhongbo Jin¹, Mark A. Jensen², Jessica M. Dorschner¹, Danielle Vsetecka¹, Shreyasee Amin³, Ashima Makol⁴, Floranne C. Ernste⁵, Thomas Osborn⁶, Kevin G. Moder⁴, Vaidehi Chowdhary³ and Timothy B. Niewold¹, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁶Dept of Rheumatology, Mayo Clinc, Rochester, MN
Background/Purpose Type I interferon (IFN) is a primary pathogenic factor in human systemic lupus erythematosus (SLE). IFN gene expression signatures have been observed in whole blood and mixed peripheral…
Abstract Number: 2687 • 2014 ACR/ARHP Annual Meeting
Estrogen-Mediated STAT1 Activation By Estrogen Receptor a Induces TLR8 Expression: A Novel Pathogenic Mechanism in Systemic Lupus Erythematosus
Nicholas Young¹, Giancarlo Valiente², Lai-Chu Wu³, Michael Bruss⁴, Stacy Ardoin², Craig Burd⁵ and Wael N. Jarjour⁶, ¹Ohio State University, Columbus, OH, ²Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Molecular & Cellular Biochemistry, The Ohio State University, Columbus, OH, ⁶Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Many autoimmune disorders, including Systemic Lupus Erythematosus (SLE) display female gender predominance. Previous studies have demonstrated significant hormonal contributions to SLE pathogenesis, including estrogen,…
Abstract Number: 1517 • 2014 ACR/ARHP Annual Meeting
Analysis of Gene Expression Fluctuation with Abatacept Highlights the Involvement of the Proteasome Pathway As a Mechanism of Action of Abatacept in Rheumatoid Arthritis
C Derambure¹, O Vittecoq^1,2, G Dzangue Tchoupou¹, Maria-Antonietta d'Agostino³, P Gaudin⁴, C Gaillez⁵, M Le Bars⁶ and T Lequerré^1,2, ¹Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²Department of Rheumatology, Rouen University Hospital, Rouen, France, ³AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁴Department of Rheumatology, University Hospital Grenoble, Grenoble, France, ⁵Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, ⁶Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Abatacept (ABA) is a biologic therapy targeting T cells, which play a major role in the pathophysiology of RA. Overall, 57.1% of patients reached…
Abstract Number: 2686 • 2014 ACR/ARHP Annual Meeting
Gene Array Analysis Reveals Unique Estrogen Signature in Peripheral Blood Mononuclear Cells of Patients with Systemic Lupus Erythematosus
Stephanie Amici¹, Nicholas A. Young², Lai-Chu Wu², Mireia Guerau¹ and Wael N. Jarjour³, ¹Health and Rehab Sciences, The Ohio State University, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disorder predominately affecting females in the reproductive age range. Estrogen is present at higher levels in this…
Abstract Number: 1494 • 2014 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor GLPG0634 Reverses an Arthritis-Specific Blood Gene Signature to Healthy State
Mate Ongenaert¹, Sonia Dupont², Béatrice Vayssière², Reginald Brys¹, Luc Van Rompaey¹, Christel Menet¹ and René Galien², ¹Galapagos NV, Mechelen, Belgium, ²Galapagos SASU, Romainville, France
Background/Purpose The 4 Janus kinases (JAK1, JAK2, JAK3 and TYK2) are cytoplasmic tyrosine kinases that mediate intracellular signaling of cytokines (e.g. certain interleukins and interferons)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].